Radiotherapy and Chemotherapy as Therapeutic Strategies in Extrahepatic Biliary Duct Carcinoma

Purpose This report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC) Patients and Methods A PubMed research identified clinical trials in BDC through April 1, 2010 including randomised controlled trials, SEER analyses and retrospective trials Additionally, publications on the technical progress of radiotherapy in or close to the liver were analysed Results Most patients with cholangiocarcinoma present with unresectable disease (80-90%), and more than half of the resected patients relapse within 1 year Adjuvant and palliative treatment options need to be chosen carefully since 50% of the patients are older than 70 years at diagnosis Adjuvant radiotherapy or chemotherapy after complete resection (R0) has not convincingly shown a prolongation of survival but radiotherapy did after R1 resection However data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy in patients with marginally resectable disease For patients with unresectable biliary tract carcinoma (Bit), palliative stenting was previously the treatment of choice But recent SEER analyses show that radiotherapy prolongs survival, relieves symptoms and contributes to biliary decompression and should be regarded as the new standard Novel technical advances in radiotherapy may allow for dose-escalation and could significantly improve outcome for patients with cholangiocarcinoma Conclusion Both the literature and recent technical progress corroborate the role of radiotherapy in BDC offering chances for novel clinical trials Progress is less pronounced in chemotherapy